HealthDay - MONDAY, July 9 (HealthDay News) -- The Exelon skin patch(rivastigmine transdermal system) has been approved by the U.S. Food andDrug Administration to treat dementia associated with mild-to-moderateAlzheimer's disease, maker Novartis Pharmaceuticals said Monday.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.